Some studies have found that individuals with diabetes have a heightened risk of morbidity and premature death associated with macrovascular complications among smokers. In this study, researchers tested an educational, interventional program led by non-doctor health professionals in order to assist adult male diabetes patients to quit smoking.
A large body of evidence from epidemiological, case-control, and cohort studies provides extensive documentation of the casual link between smoking and health risks. Some studies have even found that individuals with diabetes have a heightened risk of morbidity and premature death associated with macrovascualr complications among smokers.
India has the second highest diabetes population in the world (61 million) and also ranks second in tobacco users (275 million). Thankappan et al note that there are limited data on smoking cessation among diabetic patients in low- and middle-income countries. In this study, the researchers selected 224 adult male diabetes patients ages 18-years and older and separated them into two intervention groups. Both groups were asked and advised to quit smoking and given educational materials on smoking and diabetes. The second group also received 30 minutes of diabetes-specific counseling from a non-doctor healthcare professional.
Follow-up data were available for 87% of patients at 6 months, and researchers found that the quit rate (abstinence of smoking for at least 7 days) of the second intervention group was 51.8% and approximately 8.6 times higher that that of the first intervention group. Thankappan et al note that this disparity was also found in high-level smokers (as defined by >10 cigarettes/day). The research group concluded that “counseling by a non-doctor health professional was found to be efficacious and has the potential to significantly increase quit rates among diabetes smokers after a strong quit advise by their doctors.”
To read more about this study and to view additional information on late-breaking diabetes abstracts released at the 72nd Scientific Sessions, please visit the American Diabetes Association’s website.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More